MiR‐146a‐5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor‐alpha inhibitor adalimumab. (1st September 2018) - Mensà, E.; Recchioni, R.; Marcheselli, F.; Giuliodori, K.; Consales, V.; Molinelli, E.; Prattichizzo, F.; Rippo, M. R.; Campanati, A.; Procopio, A.D.; Olivieri, F.; Offidani, A.M.